Repatha vs Losartan: Real-World Evidence Comparison

What Are These Two Drugs Actually Doing?

Repatha and losartan sit in completely different pharmacological categories, yet both appear on the prescription list of many patients with established cardiovascular disease. Understanding their distinct mechanisms is the starting point for any rational comparison.

How Evolocumab (Repatha) Works

Evolocumab is a fully human monoclonal IgG2 antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 normally tags LDL receptors on hepatocytes for degradation. By blocking PCSK9, evolocumab allows more LDL receptors to recycle back to the cell surface, where they pull circulating LDL-C out of the bloodstream.

The result is a large, reliable drop in LDL-C. In FOURIER (N=27,564), subcutaneous evolocumab 140 mg every 2 weeks reduced LDL-C from a median baseline of 92 mg/dL to 30 mg/dL, a 59% reduction, compared with placebo. [1]

How Losartan Works

Losartan selectively blocks AT1 receptors, which mediate vasoconstriction and aldosterone release in response to angiotensin II. The net effect is arterial relaxation, reduced sodium retention, and lower blood pressure.

Losartan also carries a class-specific renal benefit. ARBs reduce intraglomerular pressure, slowing progression of diabetic nephropathy independent of systemic blood pressure. The FDA-approved indication for losartan includes hypertension, reduction of stroke risk in hypertensive patients with left ventricular hypertrophy (LVH), and nephroprotection in type 2 diabetes. [2]

The two drugs do not compete for the same biological target.

FOURIER vs LIFE: What the Landmark Trials Actually Showed

These trials cannot be compared directly because they enrolled different populations and tested different hypotheses. Still, placing their numbers side by side clarifies what each drug genuinely contributes.

FOURIER Trial (Evolocumab)

Published in the New England Journal of Medicine in 2017, FOURIER enrolled 27,564 patients with established atherosclerotic cardiovascular disease (ASCVD) who were already on optimized statin therapy. [1] The primary composite endpoint was cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization.

Key results at a median follow-up of 2.2 years:

• Primary composite endpoint: 9.8% evolocumab vs 11.3% placebo (hazard ratio 0.85, 95% CI 0.79-0.92, P<0.001) [1]
• Myocardial infarction: 27% relative risk reduction
• Stroke: 21% relative risk reduction
• The absolute LDL-C achieved (median 30 mg/dL) predicted event reduction in a near-linear dose-response relationship

No significant increase in adverse events, including new-onset diabetes or neurocognitive effects, reached statistical significance over the trial period.

LIFE Trial (Losartan)

The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) trial, published in The Lancet in 2002, enrolled 9,193 hypertensive patients aged 55-80 with ECG-confirmed LVH. [3] It compared losartan 50-100 mg daily against atenolol 50-100 mg daily over a mean follow-up of 4.8 years.

Key results:

• Primary composite (cardiovascular death, MI, stroke): 11% relative risk reduction favoring losartan (HR 0.87, 95% CI 0.77-0.98, P=0.021) [3]
• Stroke reduction: 25% relative risk reduction (P<0.001), the main driver of the composite benefit
• New-onset diabetes: significantly lower with losartan (HR 0.75)
• The blood-pressure lowering was nearly identical between groups, suggesting the stroke benefit went beyond pressure reduction alone

The LIFE investigators wrote: "Losartan was more effective than atenolol in reducing cardiovascular morbidity and mortality as well as new-onset diabetes in patients with hypertension and left ventricular hypertrophy." [3]

What the Two Trials Cannot Tell Us

Neither trial enrolled patients where the other drug would be first-line. FOURIER participants were already on statins and had established ASCVD. LIFE participants were hypertensive but not specifically selected for high LDL-C. A direct randomized head-to-head trial comparing evolocumab with losartan in a shared population does not exist and would be difficult to justify ethically, since their targets are non-overlapping.

Real-World Evidence: Registry Data and Observational Findings

Randomized controlled trials answer efficacy questions under controlled conditions. Real-world evidence (RWE) addresses effectiveness under usual care, including adherence gaps, polypharmacy, and comorbidity burden.

Evolocumab in Real-World Registries

The PROFICIO registry program, a collection of open-label extension and observational studies sponsored by Amgen, has tracked more than 17,000 patient-years of evolocumab exposure. [4] In routine clinical practice, LDL-C reductions of 55-60% are consistently observed, closely mirroring FOURIER results.

A 2022 analysis from the SWEDEHEART registry (Sweden's national coronary care database) found that PCSK9 inhibitor initiation after acute myocardial infarction was associated with a 24% lower rate of recurrent MI compared with high-intensity statin alone over a 3-year follow-up (adjusted HR 0.76, 95% CI 0.66-0.88). [5] This registry enrolled approximately 7,400 patients, giving the finding reasonable statistical weight.

Adherence, however, is a real challenge. A 2020 claims-based study in the Journal of Managed Care and Specialty Pharmacy found that only 45% of patients initiated on a PCSK9 inhibitor were still filling prescriptions at 12 months, primarily due to cost and prior-authorization barriers. [6]

Losartan in Real-World Practice

Losartan's generic availability makes adherence data more favorable. A large UK Biobank analysis (N=168,000 hypertensive patients) reported that ARBs as a class had 12-month medication possession ratios above 70%, substantially higher than specialty biologics. [7]

Real-world blood pressure control with losartan mirrors trial data for most patients. Patients with LVH or diabetic nephropathy show the most pronounced non-hemodynamic benefits, consistent with the LIFE and RENAAL trial populations. The RENAAL trial (N=1,513) demonstrated that losartan 50-100 mg daily reduced the risk of doubling of serum creatinine, end-stage renal disease, or death by 16% in type 2 diabetic nephropathy compared with placebo, on top of conventional antihypertensive therapy. [8]

The Adherence Gap in Context

The HealthRX clinical team reviewed prescribing patterns across its telehealth cohort to identify where adherence breakdowns occur most often for each drug class. Three clinical situations consistently predict non-persistence with evolocumab: prior-authorization denial on renewal (most common), injection anxiety after the first 90 days, and patient perception that "my cholesterol numbers look fine now." For losartan, the most common discontinuation reason is dry cough (even though cough is more strongly linked to ACE inhibitors, patients often attribute it to any renin-angiotensin agent) and first-dose hypotension in older adults.

Clinicians who front-load education on these specific barriers see higher 12-month persistence rates. A structured adherence conversation at the 30-day follow-up visit cuts PCSK9 inhibitor discontinuation meaningfully in routine practice.

Head-to-Head: Cardiometabolic Outcomes by Domain

Direct comparison is only valid when the domains are the same. This section maps each drug's evidence to specific cardiometabolic outcome categories.

LDL-C and Atherosclerosis

Evolocumab wins this category clearly. Losartan has no meaningful LDL-lowering mechanism. Some studies report modest indirect reductions in LDL-C with ARBs through metabolic pathways, but these effects are clinically negligible (3-5% at most) and not supported by hard outcome data. [9]

For patients with LDL-C above 70 mg/dL on maximally tolerated statin therapy, evolocumab is the evidence-based choice. The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol recommends adding a PCSK9 inhibitor for very high-risk ASCVD patients not meeting LDL-C targets on statins. [10]

Blood Pressure and Stroke

Losartan wins this category. Evolocumab has no antihypertensive mechanism. In FOURIER, baseline systolic blood pressure was approximately 130 mmHg and was not affected by evolocumab treatment.

For hypertensive patients, especially those with LVH or diabetic nephropathy, losartan (or another ARB) should be part of the treatment regimen independent of lipid management.

Renal Protection

Losartan holds a specific FDA-approved indication for renal protection in type 2 diabetic nephropathy, based on RENAAL. [8] No comparable renal-specific indication exists for evolocumab, though reducing ASCVD burden may have indirect renal benefits over time.

Heart Failure

Neither drug carries a primary heart failure indication, though the evidence base is different for each. ARBs (including losartan, studied in Val-HeFT and CHARM-Alternative) are guideline-recommended alternatives for HFrEF in patients intolerant of ACE inhibitors. [11] PCSK9 inhibitors have not demonstrated a statistically significant reduction in heart failure hospitalization in FOURIER, though the VESALIUS-CV trial (ongoing as of 2025) may add clarity.

Metabolic Effects and New-Onset Diabetes

Losartan shows a favorable signal here. In LIFE, new-onset diabetes was significantly lower with losartan vs atenolol (HR 0.75). [3] ARBs as a class improve insulin sensitivity modestly through angiotensin II blockade in skeletal muscle. Evolocumab's effect on glucose metabolism appears neutral. No significant difference in HbA1c or new-onset diabetes was observed in FOURIER. [1]

Should You Switch from Repatha to Losartan (or Vice Versa)?

This is one of the most common clinical questions sent to the HealthRX medical team. The short answer: switching between them almost never makes pharmacological sense.

The Case Against Direct Substitution

Repatha and losartan treat entirely different physiological targets. Switching from evolocumab to losartan would leave LDL-C uncontrolled while adding blood pressure management. Switching from losartan to evolocumab would lower LDL-C while leaving hypertension untreated. Neither scenario benefits the patient.

The American College of Cardiology's expert consensus from 2022 is explicit on this point: PCSK9 inhibitors are add-on therapy to statins for lipid management, and antihypertensive agents address a distinct, independently modifiable cardiovascular risk factor. [10] Managing both risk factors simultaneously is the goal.

When a Switch Might Be Discussed

There are narrow scenarios where a clinician might review the need for evolocumab. If a patient achieves dramatic LDL-C reduction through dietary intervention and intensified statin therapy, bringing LDL-C consistently below 55 mg/dL, the physician may consider a trial de-escalation. This is not equivalent to switching to losartan. It is a dose-reduction or discontinuation decision based on target attainment.

Conversely, if a patient on losartan develops new ASCVD or is found to carry a familial hypercholesterolemia mutation, adding evolocumab to the existing antihypertensive regimen is the appropriate step, not replacing losartan.

Practical Prescribing Decision Points

Three clinical markers should guide the conversation:

1. LDL-C at goal (<70 mg/dL for high-risk, <55 mg/dL for very high-risk per 2022 ACC/AHA) on current therapy: evolocumab may not be needed yet, or may be de-escalated if goal has been maintained for 12 months or more.
2. Blood pressure consistently above 130/80 mmHg: losartan or another ARB should be added regardless of PCSK9 inhibitor status.
3. Concurrent diabetic nephropathy with proteinuria: losartan has a specific evidence-based indication that evolocumab cannot substitute for.

Safety Profiles: What Real-World Pharmacovigilance Shows

Evolocumab Safety

Post-marketing data from the FDA Adverse Event Reporting System (FAERS) and the FOURIER open-label extension confirm a favorable safety profile for evolocumab. [12] The most common adverse events are injection-site reactions (6.3% vs 4.7% placebo in FOURIER), nasopharyngitis, and upper respiratory infection, all at rates comparable to placebo.

Neurocognitive concerns raised in early trials have not been substantiated. The EBBINGHAUS substudy of FOURIER (N=1,204) found no significant difference in cognitive function between evolocumab and placebo over 19 months. [13]

Losartan Safety

Losartan's safety profile over 25 years of post-marketing use is well-characterized. Hyperkalemia is the most clinically significant risk, particularly in patients with CKD or those co-prescribed potassium-sparing diuretics. A 2019 BMJ analysis of routine clinical data found that ARB-associated hyperkalemia (serum potassium above 5.5 mEq/L) occurred in approximately 3-4% of real-world CKD patients on ARBs at standard doses. [14]

The FDA issued recalls for several losartan formulations between 2018 and 2019 due to nitrosamine impurities (NDEA and NDMA) in some manufacturing batches, but subsequent testing and manufacturing changes have resolved this concern for currently marketed products. [15]

Angioedema risk is dramatically lower with ARBs than ACE inhibitors. Losartan may be safely used in most patients who experienced ACE inhibitor-induced angioedema, after a washout period.

Cost and Access: The Practical Reality

Cost is not a secondary consideration. It directly affects adherence and health outcomes.

Losartan is one of the least expensive antihypertensive agents available. Generic 50 mg tablets typically retail for $4-10 per month at major pharmacy chains. Insurance coverage is near-universal.

Evolocumab carries a list price of approximately $5,850 per year at current Amgen pricing (2024). Actual patient out-of-pocket costs vary widely depending on insurance tier, prior authorization status, and use of Amgen's copay assistance program, which can reduce costs to $0 per month for eligible commercially insured patients. Medicare patients face more restrictions under the Part D benefit structure.

The Institute for Clinical and Economic Review (ICER) has noted that PCSK9 inhibitors become cost-effective at approximately $3,000-$4,500 per year in very high-risk populations, a threshold now achievable through manufacturer discounts in many cases. [16]

Who Needs Which Drug? A Clinical Decision Summary

Most patients with established cardiovascular disease or multiple risk factors will need both drugs, prescribed for their respective indications. The decision tree is not "Repatha or losartan." It is "does this patient have uncontrolled LDL-C, uncontrolled blood pressure, or both?"

• Uncontrolled LDL-C (>70 mg/dL on maximally tolerated statin with established ASCVD): add evolocumab 140 mg every 2 weeks or 420 mg monthly.
• Hypertension (systolic >130 mmHg or diastolic >80 mmHg), especially with LVH or diabetic nephropathy: start or continue losartan 25-100 mg daily, titrating to response.
• Both conditions present: prescribe both. There are no clinically significant drug-drug interactions between evolocumab and losartan.
• Familial hypercholesterolemia (heterozygous or homozygous): evolocumab is specifically indicated; losartan is added only if hypertension coexists.

The 2023 European Society of Cardiology guidelines on dyslipidemia management set an LDL-C target of <55 mg/dL for very high-risk patients and recommend PCSK9 inhibitors when statins plus ezetimibe are insufficient. [17] For blood pressure targets in the same population, the 2023 ESC hypertension guidelines recommend <130/80 mmHg, and ARBs are first-line options with a strong evidence base. [18]

Clinicians should confirm baseline LDL-C, blood pressure, renal function (eGFR and urine albumin-to-creatinine ratio), and a full cardiovascular risk assessment before deciding which agent to initiate or whether both are warranted.